Collagen-targeted protein nanomicelles for the imaging of non-alcoholic steatohepatitis
Source abstract
Abstract
In vivo molecular imaging tools hold immense potential to drive transformative breakthroughs by enabling researchers to visualize cellular and molecular interactions in real-time and/or at high resolution. These advancements will facilitate a deeper understanding of fundamental biological processes and their dysregulation in disease states. Here, we develop and characterize a self-assembling protein nanomicelle called collagen type I binding - thermoresponsive assembled protein (Col1-TRAP) that binds tightly to type I collagen in vitro with nanomolar affinity. For ex vivo visualization, Col1-TRAP is labeled with a near-infrared fluorescent dye (NIR-Col1-TRAP). Both Col1-TRAP and NIR-Col1-TRAP display approximately a 3.8-fold greater binding to type I collagen compared to TRAP when measured by surface plasmon resonance (SPR). We present a proof-of-concept study using NIR-Col1-TRAP to detect fibrotic type I collagen deposition ex vivo in the livers of mice with non-alcoholic steatohepatitis (NASH). We show that NIR-Col1-TRAP demonstrates significantly decreased plasma recirculation time as well as increased liver accumulation in the NASH mice compared to mice without disease over 4 hours. As a result, NIR-Col1-TRAP shows potential as an imaging probe for NASH with in vivo targeting performance after injection in mice. STATEMENT OF SIGNIFICANCE: Direct molecular imaging of fibrosis in NASH patients enables the diagnosis and monitoring of disease progression with greater specificity and resolution than do elastography-based methods or blood tests. In addition, protein-based imaging probes are more advantageous than alternatives due to their biodegradability and scalable biosynthesis. With the aid of computational modeling, we have designed a self-assembled protein micelle that binds to fibrillar and monomeric collagen in vitro. After the protein was labeled with near-infrared fluorescent dye, we injected the compound into mice fed on a NASH diet. NIR-Col1-TRAP clears from the serum faster in these mice compared to control mice, and accumulates significantly more in fibrotic livers.This work advances the development of targeted protein probes for in vivo fibrosis imaging.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Celiac Disease Research and Management · Glycosylation and Glycoproteins Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Design and development of molecular imaging probes10.2174/156802610791384225 ↗
2. Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor a2 antibody by fluorescence molecular tomography10.18632/oncotarget.19569 ↗
3. Imaging biomarkers of NAFLD, NASH, and fibrosis10.1016/j.molmet.2021.101167 ↗
4. Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging10.1186/s12951-016-0239-0 ↗
5. Synthesis and characterization of dextran stabilized superparamagnetic iron oxide nanoparticles for in vivo MR imaging of liver fibrosis10.1016/j.carbpol.2013.10.015 ↗
6. Design and synthesis of SERS materials for in vivo molecular imaging and biosensing10.1002/advs.202202051 ↗
7. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities10.7150/thno.37443 ↗
8. Peptides and peptide hormones for molecular imaging and disease diagnosis10.1021/cr900361p ↗
9. L. Bohrmann, T. Burghardt, C. Haynes, K. Saatchi, U.O. Häfeli, Aptamers used for molecular imaging and theranostics - recent developments, (1838-7640 (Electronic)).
10. Protein based biomaterials for therapeutic and diagnostic applications10.1088/2516-1091/ac2841 ↗
11. Incorporation of unnatural amino acids for synthetic biology10.1039/B909200P ↗
12. Protein nanoparticles: promising platforms for drug delivery applications10.1021/acsbiomaterials.8b01098 ↗
13. Protein based therapeutic delivery agents: contemporary developments and challenges10.1016/j.biomaterials.2017.04.036 ↗
14. Effects of divalent metals on nanoscopic fiber formation and small molecule recognition of helical proteins10.1002/adfm.201101627 ↗
15. Bio-inspired protein-based nanoformulations for cancer theranostics10.3389/fphar.2018.00421 ↗
16. Self-assembled peptide amphiphiles function as multivalent binder with increased hemagglutinin affinity10.1186/1472-6750-13-51 ↗
17. Artificial protein block polymer libraries bearing two SADs: effects of elastin domain repeats10.1021/bm201083d ↗
18. Protein-engineered nanoscale micelles for dynamic 19 F magnetic resonance and therapeutic drug delivery10.1021/acsnano.8b07481 ↗
19. Temperature-induced collapse of elastin-like peptides studied by 2DIR spectroscopy10.1021/acs.jpcb.8b05221 ↗
20. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles10.1021/ja0764862 ↗
21. Collagen targeting using protein-functionalized micelles: the strength of multiple weak interactions10.1021/ja807723p ↗
22. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe10.1002/hep.28785 ↗
23. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism10.1016/j.jhepr.2019.02.004 ↗
24. Animal models of NAFLD from the pathologist's point of view10.1016/j.bbadis.2018.04.024 ↗
25. Current status of imaging in nonalcoholic fatty liver disease10.4254/wjh.v10.i8.530 ↗
26. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis10.1007/s00330-019-06331-4 ↗
27. Magnetic resonance elastography of liver: Technique, analysis, and clinical applications10.1002/jmri.23731 ↗
28. Early detection and staging of chronic liver diseases with a protein MRI contrast agent10.1038/s41467-019-11984-2 ↗
29. Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type 110.1016/j.nucmedbio.2020.11.006 ↗
30. Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression
31. Molecular MRI of collagen to diagnose and stage liver fibrosis10.1016/j.jhep.2013.06.026 ↗
32. Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin αvβ3 expression with SPECT in rat10.1002/hep.24467 ↗
33. High-resolution design of a protein loop10.1073/pnas.0707977104 ↗
34. The rosetta all-atom energy function for macromolecular modeling and design10.1021/acs.jctc.7b00125 ↗
35. A pareto-optimal refinement method for protein design Scaffolds10.1371/journal.pone.0059004 ↗
36. Matching protein surface structural patches for high-resolution blind peptide docking10.1073/pnas.2121153119 ↗
37. Rapid search for tertiary fragments reveals protein sequence–structure relationships10.1002/pro.2610 ↗
38. Method to overcome inefficiencies in site-directed mutagenesis of a/t-rich dna
39. N-terminal aliphatic residues dictate the structure, stability, assembly, and small molecule binding of the coiled-coil region of cartilage oligomeric matrix protein10.1021/bi900534r ↗
40. Adler · 1973 · 675
41. Smoothing and differentiation of data by simplified least squares procedures10.1021/ac60214a047 ↗
42. CONTIN: a general purpose constrained regularization program for inverting noisy linear algebraic and integral equations10.1016/0010-4655(82)90174-6 ↗
43. Supramolecular assembly and small-molecule binding by protein-engineered coiled-coil fibers10.1021/acs.biomac.2c01031 ↗
44. Quantifying amyloid fibrils in protein mixtures via infrared attenuated-total-reflection spectroscopy10.1007/s00216-015-8623-4 ↗
45. 5-Dodecanoylaminofluorescein as a probe for the determination of critical micelle concentration of detergents using fluorescence anisotropy10.1016/j.ab.2005.01.006 ↗
46. Binding kinetics of ligands acting at GPCRs10.1016/j.mce.2019.01.018 ↗
47. Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis10.1016/S0026-895X(25)08761-9 ↗
48. DIAPH1 mediates progression of atherosclerosis and regulates hepatic lipid metabolism in mice10.1038/s42003-023-04643-2 ↗
49. RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism10.1172/jci.insight.137289 ↗
50. Development and characterization of a clinically relevant mouse model of melanoma brain metastasis10.1111/pcmr.12114 ↗
51. Melanoma-secreted amyloid beta suppresses neuroinflammation and promotes brain metastasis10.1158/2159-8290.CD-21-1006 ↗
52. Ultrasonography-guided intracardiac injection: an improvement for quantitative brain colonization assays10.1016/j.ajpath.2013.03.003 ↗
53. Method for picrosirius red-polarization detection of collagen fibers in tissue sections10.1007/978-1-4939-7113-8_26 ↗
54. Design of decorin-based peptides that bind to collagen I and their potential as adhesion moieties in biomaterials10.1002/anie.201505227 ↗
55. Targeting collagen for diagnostic imaging and therapeutic delivery10.1016/j.jconrel.2016.01.007 ↗
56. PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta10.1093/bioinformatics/btq007 ↗
57. Decorin core protein (decoron) shape complements collagen fibril surface structure and mediates its binding10.1371/journal.pone.0007028 ↗
58. Sub-angstrom modeling of complexes between flexible peptides and globular proteins10.1002/prot.22716 ↗
59. Accurate prediction of protein structures and interactions using a three-track neural network10.1126/science.abj8754 ↗
60. Truncation, randomization, and selection: Generation of a reduced length c-jun antagonist that retains high interaction stability10.1074/jbc.M111.221267 ↗
61. Elasticity and inverse temperature transition in elastin10.1021/acs.jpclett.5b01890 ↗
62. The molecular basis for the inverse temperature transition of elastin10.1006/jmbi.2000.4306 ↗
63. Fluorescence self-quenching from reporter dyes informs on the structural properties of amyloid clusters formed in vitro and in cells10.1021/acs.nanolett.6b03686 ↗
64. Exploiting protein N-terminus for site-specific bioconjugation10.3390/molecules26123521 ↗
65. Examination of the secondary structure of proteins by deconvolved FTIR spectra10.1002/bip.360250307 ↗
66. Circular dichroism techniques: biomolecular and nanostructural analyses- a review10.1111/j.1747-0285.2009.00847.x ↗
67. The use and misuse of FTIR spectroscopy in the determination of protein structure10.3109/10409239509085140 ↗
68. Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation10.1074/jbc.M701088200 ↗
69. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III10.1172/JCI111729 ↗
70. Preventing intense false positive and negative reactions attributed to the principle of ELISA to re-investigate antibody studies in autoimmune diseases10.1016/j.jim.2014.03.013 ↗
71. Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity10.1016/j.jim.2009.10.002 ↗
72. Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera10.1016/j.bios.2008.11.015 ↗
73. Development and applications of surface plasmon resonance-based von willebrand factor– collagen binding assay10.1006/abio.2001.5555 ↗
74. Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeutics10.1016/j.jconrel.2015.09.048 ↗
75. Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis10.1016/j.cmet.2020.03.010 ↗
76. Volume of distribution10.12793/tcp.2016.24.2.74 ↗
77. Polymeric micelles for nano-scale drug delivery10.1016/j.reactfunctpolym.2010.10.009 ↗
78. The use of propane/isopentane mixtures for rapid freezing of biological specimens10.1111/j.1365-2818.1981.tb02475.x ↗
79. Digital image analysis of picrosirius red staining: a robust method for multi-organ fibrosis quantification and characterization10.3390/biom10111585 ↗
80. Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies10.3346/jkms.2019.34.e14 ↗
81. Noninvasive diagnosis of NAFLD and NASH10.3390/cells9041005 ↗
82. Biomarkers in nonalcoholic fatty liver disease10.1155/2014/757929 ↗
83. Fibrosis in chronic liver diseases: diagnosis and management10.1016/j.jhep.2004.12.008 ↗
84. Karsdal · 2017 · 43
85. Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates10.1074/jbc.M709319200 ↗
86. Collagen interactions: drug design and delivery10.1016/j.addr.2015.11.013 ↗
87. Computational modeling of type I collagen fibers to determine the extracellular matrix structure of connective tissues10.1093/protein/gzi037 ↗
88. Designing collagen-binding peptide with enhanced properties using hydropathic free energy predictions10.3390/app13053342 ↗
89. COMP acts as a catalyst in collagen fibrillogenesis10.1074/jbc.M705735200 ↗
90. Cartilage oligomeric matrix protein: COMPopathies and beyond10.1016/j.matbio.2018.02.023 ↗
91. Lysine post-translational modifications of collagen10.1042/bse0520113 ↗
92. Pre-crosslinked polymeric collagen in 3-D models of mechanically stiff tissues: blended collagen polymer hydrogels for rapid layer fabrication10.1016/j.actbio.2014.08.038 ↗
93. Changes in the cross-linking of collagen from rat tail tendons due to diabetes10.1016/S0021-9258(19)30029-8 ↗
94. Blood volume determination in the mouse10.1113/jphysiol.1973.sp010086 ↗
95. Current strategies in extending half-lives of therapeutic proteins10.1016/j.jconrel.2019.02.016 ↗
96. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination10.1016/j.jconrel.2016.01.020 ↗
97. Nonalcoholic fatty liver disease and chronic kidney disease: a review of links and risks10.2147/CEG.S226130 ↗
98. Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH)10.1016/j.kint.2023.12.009 ↗
99. Mechanisms of fibrosis development in nonalcoholic steatohepatitis10.1053/j.gastro.2019.11.311 ↗
100. Role of angiogenesis in the pathogenesis of NAFLD10.3390/jcm10071338 ↗